In recent years, traditional surgery, chemotherapy, and radiotherapy alone may fail to acquire satisfactory effects for patients. However, radiotherapy combined with immunotherapy will enhance the effect. Immune checkpoint inhibitors and immunotherapy drugs can make the body produce systemic tumor-specific immunity, eliminating metastases and eradicating tumors with fewer or no side effects. They have revolutionized cancer treatment. Although these therapies have been remarkably successful in treating various cancers, many patients still don’t acquire clinically satisfactory benefits. With the development of various anti-cancer drugs, scientists have promoted the transformation of tumor therapy from the application of target drugs in the past, such as PD-1/PD-L1, to combining immunotherapy treatment, including nanomedicine, and radio-immunotherapy, etc., which will extend the benefits of immunotherapy to a broader patient population. This research topic aims to promote interdisciplinary collaboration and innovation therapy, which will advance personalized immunotherapy approaches and enhance clinical immunotherapy outcomes for patients with no-response cancer types. The focus is on understanding how effective drugs and combination strategies in immunotherapy are to improve the therapeutic benefits for cancer patients. This topic includes, but is not limited to, the following sub-topics:1. Cancer control via nanomedicine, cellular immunotherapy, radioimmunotherapy, and combination therapies2. Personalized immunotherapy: Therapeutic innovations and future directions3. Exploring the potential prognosis marker in anti-cancer drugs combined immunotherapy4. 3D technology and its impact on immunotherapy efficacy evaluation5. Immune modulation strategies to enhance immunotherapy6. Harnessing innate immunity in cancer therapy: pathways like STING and others7. CAR-T/NK drug alone or combined therapy for hematologic malignancies and solid tumors8. Machine learning application in combination therapeutics for improved patient outcomes9. Utilizing AI to analyze innovative combination immunotherapies strategies in precision oncology10. Predicting responses and prognoses in anti-cancer drugs combined immunotherapy
In recent years, traditional surgery, chemotherapy, and radiotherapy alone may fail to acquire satisfactory effects for patients. However, radiotherapy combined with immunotherapy will enhance the effect. Immune checkpoint inhibitors and immunotherapy drugs can make the body produce systemic tumor-specific immunity, eliminating metastases and eradicating tumors with fewer or no side effects. They have revolutionized cancer treatment. Although these therapies have been remarkably successful in treating various cancers, many patients still don’t acquire clinically satisfactory benefits. With the development of various anti-cancer drugs, scientists have promoted the transformation of tumor therapy from the application of target drugs in the past, such as PD-1/PD-L1, to combining immunotherapy treatment, including nanomedicine, and radio-immunotherapy, etc., which will extend the benefits of immunotherapy to a broader patient population. This research topic aims to promote interdisciplinary collaboration and innovation therapy, which will advance personalized immunotherapy approaches and enhance clinical immunotherapy outcomes for patients with no-response cancer types. The focus is on understanding how effective drugs and combination strategies in immunotherapy are to improve the therapeutic benefits for cancer patients. This topic includes, but is not limited to, the following sub-topics:1. Cancer control via nanomedicine, cellular immunotherapy, radioimmunotherapy, and combination therapies2. Personalized immunotherapy: Therapeutic innovations and future directions3. Exploring the potential prognosis marker in anti-cancer drugs combined immunotherapy4. 3D technology and its impact on immunotherapy efficacy evaluation5. Immune modulation strategies to enhance immunotherapy6. Harnessing innate immunity in cancer therapy: pathways like STING and others7. CAR-T/NK drug alone or combined therapy for hematologic malignancies and solid tumors8. Machine learning application in combination therapeutics for improved patient outcomes9. Utilizing AI to analyze innovative combination immunotherapies strategies in precision oncology10. Predicting responses and prognoses in anti-cancer drugs combined immunotherapy